Cloves, known for their potent analgesic, anti-inflammatory, and antiseptic properties, are used in various therapeutic forms, including oral and topical solutions. However, the strong taste of the oil and the difficulty in controlling the necessary doses to ensure treatment efficacy have always been major obstacles in producing high-quality supplements. 

The raw material supplier for supplements, IPS, has introduced a highly innovative solution: microcapsules containing clove oil. 

The clove oil microcapsules produced by IPS represent a significant advancement in the field of dietary supplements and nutraceuticals. Through a microencapsulation by coacervation process, which encloses the oil in a gastro-resistant polymeric membrane, the therapeutic properties are preserved while masking the pungent taste. 

With sizes ranging from 100 to 600 µm and an oil content that can reach up to 85%, these microcapsules ensure unparalleled effectiveness. In addition, the controlled release of the active substance is another advantage: a technology that ensures the active ingredients are absorbed at the optimal point in the intestine, maximizing the desired therapeutic effect and reducing the risk of side effects. 

The presence of components such as eugenol, which makes up to 88% of the encapsulated oil, further enhances the anti-inflammatory and analgesic properties of the final product. But the real breakthrough lies in the possibility of combining substances that would otherwise be incompatible, expanding the formulation possibilities for supplement manufacturers. 

In an increasingly competitive market, the ability to offer products that combine efficacy, safety, and convenience has become crucial. IPS clove microcapsules allow supplement manufacturers to effectively meet these demands while staying true to consumer expectations.